KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Finished Goods (2016 - 2018)

Teva Pharmaceutical Industries' Finished Goods history spans 9 years, with the latest figure at $2.7 billion for Q4 2018.

  • For the quarter ending Q4 2018, Finished Goods fell 0.89% year-over-year to $2.7 billion, compared with a TTM value of $2.7 billion through Dec 2018, down 0.89%, and an annual FY2018 reading of $2.7 billion, down 0.89% over the prior year.
  • Finished Goods for Q4 2018 was $2.7 billion at Teva Pharmaceutical Industries, down from $2.7 billion in the prior quarter.
  • The five-year high for Finished Goods was $2.8 billion in Q4 2016, with the low at $2.1 billion in Q4 2015.
  • Average Finished Goods over 5 years is $2.6 billion, with a median of $2.7 billion recorded in 2017.
  • Year-over-year, Finished Goods fell 11.65% in 2014 and then skyrocketed 38.15% in 2016.
  • Tracing TEVA's Finished Goods over 5 years: stood at $2.3 billion in 2014, then fell by 9.61% to $2.1 billion in 2015, then surged by 38.15% to $2.8 billion in 2016, then decreased by 5.05% to $2.7 billion in 2017, then fell by 0.89% to $2.7 billion in 2018.
  • Per Business Quant, the three most recent readings for TEVA's Finished Goods are $2.7 billion (Q4 2018), $2.7 billion (Q3 2018), and $2.7 billion (Q2 2018).